KOLMAR-BNH
Kolmar BNH (KOSDAQ: 200130), a manufacturer of HemoHIM, a health-enhancing functional food, has emerged as a frontrunner in the global Original Development Manufacturing (ODM) market, owing to its pioneering investments in research and development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510895890/en/
A researcher from Kolmar BNH Health Food Lab. (Photo: Kolmar BNH)
Founded in 2005, Kolmar BNH is an ODM company for health-functional food products. ODM enterprises, encompassing various sectors from trend analysis to R&D, product conceptualization, manufacturing, and quality assurance, cater to customers with entrepreneurial aspirations. This framework facilitates opportunities for individuals with a passion for business and ideas.
The cornerstone of Kolmar BNH's competitiveness lies in its technological adeptness, underpinned by substantial R&D investments. The company annually allocates over 2% of its sales revenue to R&D expenditures, bolstering its capabilities by employing more than 30% of its workforce as researchers. The Health Food Lab, an arm of Kolmar BNH, comprising over 100 researchers with master's and doctoral degrees, is dedicated to pioneering new formulations and functionalities.
Kolmar BNH maintains relationships with over 300 domestic and international clients, leveraging its R&D prowess that has evolved over an extended period. Among its key clients is the Korean branch of Haleon, a global healthcare conglomerate, for which Kolmar BNH manufactures the flagship vitamin product 'Centrum' distributed in Korea.
HemoHIM, distributed by Atomy, represents a technology-intensive product of Kolmar BNH. The primary ingredient, the ‘HemoHIM Extract Complex of Angelica gigas, etc.’, is Korea's first individually recognized ingredient enhancing immune function, developed in collaboration with the Korea Atomic Energy Research Institute. This product has penetrated markets in 19 countries, including Australia, the United States, Thailand, Taiwan, Central Asia, and South America.
‘HemoHIM G’, tailored for the European market, is another testament to Kolmar BNH's R&D capabilities. This export-oriented product has been meticulously formulated to comply with diverse food regulations across European nations, incorporating carefully selected ingredients such as Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora. The flavor and aroma have also been refined in order to satisfy the preferences of European consumers.
Kolmar BNH's stellar performance in sales among Korean health-functional food ODM firms can be attributed to the success of HemoHIM. Achieving sales exceeding KRW 600 billion within a decade and a half of its inception, the company was honored with the ‘200 Million Dollar Export Tower’ at the Korea International Trade Association’s ‘Trade Day’ ceremony in 2021.
Kolmar BNH aims to bolster its global market competitiveness by prioritizing R&D efforts in raw material development, with emphasis on uncovering additional efficacies through in-depth research of Hemohim G.
An official from Kolmar BNH said, “As a leading ODM company in Korea's health-functional food sector, Kolmar BNH remains steadfast in its commitment to R&D, striving to deliver customer-centric services. We endeavor to captivate global clientele by showcasing the technological expertise amassed through years of dedicated innovation.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510895890/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom